Axxam announces appointment of Prof. Hanno Wild to Board of Directors
Axxam shareholders approved the appointment of Prof. Dr. Hanno Wild as member of the Board of Directors.
Prof. Dr. Hanno Wild is Head of Global Lead Generation and Optimization within Global Drug Discovery at Bayer Schering Pharma (BSP). Prof. Wild is responsible for all research activities with respect to generation and optimization of new chemical entities (NCE) up to preclinical development at all BSP research sites (Beijing, Berlin, Wuppertal).
Before the Schering integration in 2007 Prof. Wild was Senior Vice President Discovery Europe, heading all BHC Pharma research activities at the German research site in Wuppertal. From 2002-2006 he worked as Vice President and Head of Medicinal Chemistry in Wuppertal. Before that time he had various responsibilities at the Medicinal Chemistry Department in Wuppertal, e. g. as a section head, responsible for the Therapeutic area “Atherosclerosis“. From 1994-1996 he was delegated to the Bayer Pharma Research Center in West Haven, Connecticut. In West Haven Hanno started the first projects of Bayer in the cancer field including the project leading to the marketed product Nexavar. In 2008 Hanno was appointed honorary professor at the Rheinische Friedrich-Wilhelms-Universität, Bonn.